atenolol has been researched along with naloxone in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Penz, WP; Pugsley, MK; Walker, MJ; Wong, TM | 1 |
| Evans, RG; Ludbrook, J; Potocnik, SJ | 1 |
| Jones, LF; Laskey, RE; Tackett, RL | 1 |
| Ludbrook, J; Pavia, JM; Rutter, PC | 1 |
| Kuriyama, K; Muramatsu, M; Ohkuma, S; Ping, ZP; Tamura, J | 1 |
| Funada, M; Misawa, M; Misu, Y; Sugano, Y; Suzuki, T; Tsubai, M; Ueda, H | 1 |
| Aston-Jones, G; Harris, GC | 1 |
| Forsling, ML; Yasin, SA | 1 |
1 review(s) available for atenolol and naloxone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
20 other study(ies) available for atenolol and naloxone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Drug Interactions; Electrocardiography; Heart Rate; Male; Naloxone; Potassium; Pyrrolidines; Rats; Rats, Inbred Strains | 1992 |
Intracisternal naloxone and cardiac nerve blockade prevent vasodilatation during simulated haemorrhage in awake rabbits.
Topics: Acute Disease; Animals; Atenolol; Central Nervous System; Cisterna Magna; Heart; Hemodynamics; Hemorrhage; Injections; Injections, Intraventricular; Naloxone; Nerve Block; Parasympatholytics; Pericardium; Procaine; Rabbits | 1989 |
Naloxone pretreatment blocks the hypotensive effects of atenolol in SHR and WKY rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Heart Rate; Male; Naloxone; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Yohimbine | 1989 |
Analysis of mechanisms responsible for the bradycardic action of naloxone after haemorrhage in the conscious rabbit.
Topics: Animals; Atenolol; Blood Pressure; Bradycardia; Ganglionic Blockers; Heart Rate; Hemorrhage; N-Methylscopolamine; Naloxone; Pericardium; Pressoreceptors; Rabbits; Scopolamine Derivatives; Sympathectomy, Chemical | 1987 |
Differential effects of morphine withdrawal on cerebral beta 1- and beta 2-adrenergic receptors.
Topics: Albuterol; Animals; Atenolol; Cerebral Cortex; Dihydroalprenolol; Humans; Male; Morphine; Morphine Dependence; Naloxone; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Receptors, Adrenergic, beta; Substance Withdrawal Syndrome | 1981 |
Role of beta-adrenoceptors in the expression of morphine withdrawal signs.
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Animals; Atenolol; Behavior, Animal; Benzylamines; Injections, Subcutaneous; Male; Mice; Morphine; Morphine Dependence; Naloxone; Propanolamines; Receptors, Adrenergic, beta; Substance Withdrawal Syndrome | 1994 |
Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Avoidance Learning; Male; Naloxone; Narcotics; Propranolol; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome | 1993 |
Mechanisms of melatonin inhibition of neurohypophysial hormone release from the rat hypothalamus in vitro.
Topics: Animals; Atenolol; Atropine; Haloperidol; Hypothalamus; Ibuprofen; In Vitro Techniques; Male; Mecamylamine; Melatonin; Naloxone; Oxytocin; Phentolamine; Rats; Rats, Wistar; Receptors, Neurotransmitter; Reproducibility of Results; Vasopressins | 1998 |